IBI3032 / Innovent Biologics - LARVOL DELTA

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese Adults (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • PK/PD data • Metabolic Disorders

IBI3032: An Orally Bioavailable Nonpeptidic GLP-1 Receptor Agonist Advancing through Phase 1 Clinical Trials (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • P1 data • Metabolic Disorders

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) | Trial completion date: Mar 2026 ➔ Sep 2026 | Trial primary completion date: Nov 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study of IBI3032 in Chinese Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=79 | Active, not recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Study of IBI3032 in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) | Active, not recruiting ➔ Completed

Trial completion

A Study of IBI3032 in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study of IBI3032 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Fortvita Biologics (USA)Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study of IBI3032 in Chinese Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)

New P1 trial • Genetic Disorders • Obesity

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=92 | Recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=92 | Not yet recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)

New P1 trial • Genetic Disorders • Obesity

A Study of IBI3032 in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) | Not yet recruiting ➔ Recruiting

Enrollment open

A Study of IBI3032 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Fortvita Biologics (USA)Inc.

New P1 trial

A Study of IBI3032 in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)

New P1 trial

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032 (PRNewswire) - "Innovent Biologics...announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial of IBI3032, the company's novel oral GLP-1R agonist....The Phase 1 clinical trials of IBI3032 are planned to be conducted concurrently in China and the U.S. Dosing in healthy volunteers and overweight or obese participants is expected to begin in the second half of 2025."

IND • New P1 trial • Obesity